F-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) is actually considered as the standard technique to assess and monitor the metabolic response to therapy and to define minimal residual disease (MRD) status outside the bone marrow (BM) in multiple myeloma (MM) patients. In this regard, standardization of image criteria and definition of cut-offs for positivity/negativity is of highly importance.

Aim of the present study was to prospectively evaluate FDG-PET/CT at diagnosis and prior to maintenance therapy in a joined analysis of a sub-group of patients with newly diagnosed transplant-eligible MM, enrolled in 2 independent European randomized phase III trials (EMN02/HO95 and IFM2009) (Cavo M et al, Blood 2017 abs; Attal M et al, NEJM 2017). The primary end-point was to standardize PET/CT evaluation by centralized imaging and revision and to define criteria for PET negativity after therapy (MRD definition).

Conclusion: 

FDG PET/CT was confirmed to be a reliable predictor of outcomes in newly diagnosed MM, regardless of treatment. Reduction of FDG uptake lower than the liver after therapy, both in the FLs and in the BM (FS and BMS), was an independent predictor for improved PFS and OS. Findings from this analysis could be proposed as standardized criteria to define PET negativity after therapy, confirming the value of Deauville scores in MM.

Authors:

Elena Zamagni, MD, Cristina Nanni, Luca Dozza, MSc, Thomas Carlier, Paola Tacchetti, MD, PhD, Annibale Versari, Stephane Chauvie, Andrea Gallamini, MD, Michel Attal, Barbara Gamberi, MD, Denis Caillot, Francesca Patriarca, MD, Margaret Macro, Mario Boccadoro, MD, Laurent Garderet, Stefano Fanti, Aurore Perrot, Francesca Gay, MD, Pieter Sonneveld, Lionel Karlin, MD, Michele Cavo, MD, Caroline Bodet-Milin, Philippe Moreau and Francoise Kraeber-Bodere

 


ABOUT ELENA ZAMAGNI, MD PhD

Elena Zamagni MD, PhD, is an Assistant Professor of Hematology at the University of Bologna, Italy. She received her medical degree from the University of Bologna. She has published over 90 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She is an active member of the board of the GIMEMA myeloma working party and she has cooperated in the Scientific secretary and as principal investigator in several national randomized trials in multiple myeloma. She is a member of the Italian Society of Haematology and of the International Myeloma Working Group. She is serving on the EHA’s Scientific Program Committee since 2017. Visit Dr. Elena Zamagni’s full biography.

Previous Post
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Next Post
Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.